Vancouver, British Columbia, April 1, 2021 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT: 50N) (TSX-V: NSP) (OTC: NSPDF) provides an update on the Health Canada approved, COVID-19 phase 2 clinical trial and strategic outlook for Plasm Pharmaceutical and development of the target drug CavaltinibTM.